SOPHiA GENETICS: Net Dollar Retention Surges to 117% as CEO Prepares Exit and Biopharma Momentum Finally Materializes
Q1 2026 Earnings Call, May 5, 2026 — 22% Revenue Growth, Guidance Reaffirmed, Leadership Transition Imminent
SOPHiA GENETICS opened 2026 with its strongest quarterly performance in recent memory, posting 22% year-over-year revenue growth to $21.7 million and processing a record 108,000 genomic analyses in the quarter. March alone saw more than 40,000 patients analyzed, a new single-month company record. But the headline numbers almost undersell what this quarter revealed: the platform's expansion engine is decisively reaccelerating after two years of sluggish same-store growth, biopharma revenue has turned positive after a prolonged drought, and founder and CEO Jurgi Camblong is stepping down to Executive Chairman in June, handing the reins to President Ross Muken.
The Expand Engine Turns: Net Dollar Retention at 117%
The single most important number in this print is net dollar retention, which jumped to 117% in Q1 2026 from just 103% in the year-ago period. This is the metric that has historically been the soft underbelly of the SOPHiA story — the company was landing customers but not reliably growing within them. That dynamic has now visibly shifted. Muken was direct about the strategic pivot: "We were very intentional this year versus the last two years of really focusing on the expand." He also noted that this type of organic expansion carries very little incremental cost, making it a high-ROI lever as the company presses toward EBITDA breakeven.
The drivers are a mix of new application uptake and favorable underlying market conditions. Liquid biopsy analyses reached 3,000 in Q1, up more than 100% year-over-year, though from a still-small base. Enhanced exomes are beginning to contribute, with rare and inherited disease volumes growing over 20%. Hem/Onc revenue grew 24%. Three expand deals in Europe were each valued at over $1 million in annual contract value. Annualized revenue churn remained below 1%, which continues to be a genuinely exceptional retention figure for a healthcare SaaS platform.
Liquid Biopsy: 100 Signed Accounts, Half Still Implementing
The MSK Access and MSK Impact applications — decentralized versions of Memorial Sloan Kettering's proprietary tests that SOPHiA has now distributed globally — have crossed 100 signed customer accounts less than two years after commercial launch. Notable Q1 signings include Maastricht UMC in the Netherlands, Ospedale Niguarda in Milan, and Ruhr University Bochum in Germany. The milestone is strategically significant because, as Muken pointed out, liquid biopsy testing at scale essentially did not exist outside the United States before SOPHiA began deploying these applications globally.
However, investors should note the caveat: roughly half of those 100 signed accounts are still in implementation and have yet to generate revenue. The ramp in individual accounts has been uneven. Muken acknowledged that oncologist education remains a bottleneck in some geographies, and that adoption curves differ meaningfully by country and cancer type. "We'd obviously like to see that inflect more materially," he said. The company is pointing to ASCO and ESMO data presentations as catalysts for driving utilization higher in the second half. The revenue contribution from liquid biopsy is expected to be more meaningful in H2 2026 and into 2027.
Gross Margin Holds Near 75% — Platform Modernization Paying Off
Adjusted gross margin came in at 75.4%, essentially flat with 75.7% in Q1 2025 but ahead of what some had feared given the addition of more compute-intensive applications. The company's two-year "Gen 2" platform modernization appears to be delivering on its promise of cloud compute and storage efficiency. Muken suggested there is further scalability remaining even as more complex solutions come online. The company continues to guide for modest full-year gross margin expansion beyond 2025 levels, and management flagged that the pharma business is the one segment where quarterly lumpiness could create noise in the gross margin line.
Biopharma: Finally in the Green, But Management Stays Conservative
After an extended period of biopharma revenue weakness that required strategic restructuring, the segment turned positive in Q1, contributing modestly to overall growth. Recent contract signings with AstraZeneca, Johnson and Johnson, Kartos, and others are beginning to generate revenue. Muken was careful to temper enthusiasm: "We're not declaring victory. We're just starting to show kind of the right level of performance here, but it's certainly materially better than where we were even 12 months ago." Management declined to revise biopharma assumptions higher in the full-year guide, maintaining conservative forecasting until the reacceleration is more firmly established.
The strategic narrative around pharma has also sharpened. SOPHiA is explicitly positioning its global diagnostic network as an end-to-end drug lifecycle asset — from companion diagnostics during clinical trials through post-launch real-world evidence generation and patient selection. Muken made the competitive logic explicit: "You can have one harmonized global solution in all markets that doesn't require large bridging studies, that doesn't require some hybrid mix of seven or ten laboratories around the world." Partnerships with Myriad Genetics in the U.S. and Additiv Innovations in Japan are advancing toward a hybrid global CDx infrastructure, though details remain limited.
U.S. Momentum Building, Latin America a Drag
U.S. volumes grew 28% year-over-year in Q1, and the Mount Sinai partnership expansion — adding haemato-oncology and solid tumor testing to the New York market — is emblematic of a broader decentralization trend that the company believes is now structurally entrenched in the U.S. SOPHiA now counts NYU Langone and Memorial Sloan Kettering among its New York-area partners. APAC volumes grew 31% and EMEA revenue grew 30%, with particularly strong performance in the U.K., Belgium, and Switzerland.
Latin America is the notable blemish. Revenue in the region fell more than 30% year-over-year in Q1, and management acknowledged the performance has been disappointing for several consecutive quarters. A leadership change has been made, and Muken indicated he visited Brazil, Colombia, and Argentina personally in recent weeks. Brazil is identified as the primary problem area. The company expressed cautious optimism for a recovery, partly tied to new drug approvals that could drive testing volumes in specific geographies. Given the region's small absolute contribution to total revenue, the financial impact is limited, but the strategic signals bear watching.
Cash Burn Widens, But for Identifiable Reasons
Cash burn of $19.5 million in Q1 was a significant step up from $11.7 million in Q1 2025 and requires context. Management cited three specific factors: elevated bonus and commission payouts tied to strong 2025 performance, approximately $1 million in capital expenditure for a new lab at Swiss headquarters, and ongoing legal defense costs related to the Guardant Health patent infringement lawsuit. The Guardant litigation — filed in the U.K. and at the Unified Patent Court in Paris, alleging SOPHiA's MSK Access application infringes Guardant patents — cost approximately $1.4 million in Q1 legal expenses. The UPC rejected Guardant's request for provisional measures in January and ordered Guardant to pay SOPHiA $700,000 in interim costs, of which $500,000 was received in March and $200,000 in April. The Swiss franc's 14% appreciation against the U.S. dollar year-over-year is also inflating translated cost figures without reflecting any actual deterioration in local-currency cost discipline.
The company ended Q1 with $65.4 million in cash, which includes $14.5 million in ATM proceeds raised during the quarter. In January, SOPHiA also expanded its credit facility with Perceptive Advisors by $25 million. The combination of ATM usage and credit facility expansion signals that management is actively managing its runway, even as it reiterates confidence in reaching its profitability targets. The company continues to guide for adjusted EBITDA approaching breakeven by end of 2026 and turning positive in the second half of 2027.
CEO Transition: Camblong to Executive Chair, Muken Takes the Wheel
Jurgi Camblong's final earnings call as CEO was this one. He transitions to Executive Chairman in June, with Ross Muken assuming the CEO role. Camblong co-founded the company fifteen years ago and has been the public face of its clinical AI positioning throughout its listed life. His departure from the operational seat is not a surprise — the transition has been telegraphed — but it still represents a meaningful change in day-to-day leadership at a moment when the company is navigating a critical inflection toward profitability. Muken, who joined as President and has been driving both the commercial organization and the pharma strategy rebuild, will now formally lead. His fluency with both the technology and the financial discipline of the business was evident throughout the call.
Full-Year Guidance Reaffirmed at $92 to $94 Million
SOPHiA reaffirmed its 2026 revenue guidance of $92 million to $94 million, representing 20% to 22% reported growth, and its adjusted EBITDA loss guidance of $29 million to $32 million versus $41.5 million in 2025. Growth remains guided as back-half weighted, driven by the onboarding of the 124 customers signed in 2025 and continued ramp of liquid biopsy, enhanced exomes, and MSK applications. Average selling price per analysis, which came in around $195 in Q1 on a blended basis, is expected to continue drifting upward as higher-ASP applications represent a growing share of the mix. The Swiss franc volatility remains an acknowledged risk to reported results without changing the underlying business trajectory.
SOPHiA GENETICS SA Deep Dive
Business Model and Monetization Engine
SOPHiA GENETICS operates as a cloud-native software technology company, serving as the analytical brain for precision medicine rather than functioning as a traditional diagnostic laboratory. The company's core asset is the SOPHiA DDM platform, an artificial intelligence-driven software-as-a-service solution designed to standardize, compute, and analyze raw digital health data. When a hospital or clinical laboratory sequences a patient's DNA using hardware from manufacturers like Illumina, the output is a massive, noisy dataset. SOPHiA's platform ingests this data, applies machine learning algorithms to filter out the noise, and identifies clinically relevant genetic variants to aid physicians in matching patients with targeted therapies. The company intentionally avoids the capital-intensive business of operating physical laboratories or manufacturing wet-lab chemical reagents, focusing entirely on the secondary and tertiary layers of bioinformatics data analysis.
The monetization engine is fundamentally consumption-based, driven by a pay-per-analysis revenue model. Healthcare institutions access the platform with minimal upfront software costs but pay SOPHiA a fee each time a patient's genomic profile is analyzed through the system. This creates a highly scalable revenue stream directly tied to testing volumes at the hospital level. Alongside the pay-per-use structure, the company generates revenue through dry-lab access subscriptions and bundled software sales. Furthermore, SOPHiA has begun monetizing its aggregated, anonymized clinical data by selling insights and predictive algorithms to biopharmaceutical companies for drug discovery and clinical trial optimization, creating a high-margin secondary revenue stream from data that has already been paid for by clinical customers.
Customer Ecosystem and Competitive Landscape
The company's primary customer base consists of academic medical centers, regional hospital systems, and independent pathology laboratories. As of the first quarter of 2026, SOPHiA served 537 core genomics customers globally, including prestigious institutions such as Mount Sinai, NYU Langone Health, and Memorial Sloan Kettering Cancer Center. On the biopharmaceutical side, the company partners with major drug developers, including a recently expanded relationship with AstraZeneca, to leverage real-world data for oncology research. The end customers are ultimately oncologists and medical geneticists who rely on SOPHiA's clinical reports to make life-and-death therapeutic decisions for patients with cancer and rare inherited disorders.
The competitive arena is intensely fragmented and categorized by three distinct rival archetypes. The first consists of massive, centralized reference laboratories such as Tempus AI, Foundation Medicine, and Caris Life Sciences. These entities require hospitals to physically ship tissue or blood samples to their proprietary facilities for end-to-end processing. The second group comprises pure-play bioinformatics software competitors like Fabric Genomics, PierianDx, and Syapse, which compete directly with SOPHiA to power in-house hospital laboratories. The third threat comes from the sequencing hardware giants themselves, primarily Illumina with its Connected Analytics and DRAGEN software, attempting to bundle analysis software with their hardware sales. While definitive market share data in the bioinformatics sub-segment is guarded, SOPHiA's processing of 108,000 analyses in a single quarter positions it as a dominant player in the decentralized clinical genomics software market, though it remains a smaller entity relative to centralized juggernauts like Tempus AI.
Competitive Advantages and The Decentralized Moat
SOPHiA's primary competitive advantage is rooted in its decentralized philosophy. Hospitals increasingly prefer to keep tissue samples and patient data in-house to maintain control, generate faster turnaround times, and retain the reimbursement economics of the test. SOPHiA enables this by providing enterprise-grade analytics to regional labs that lack the bioinformatic engineering talent to build software internally. Because SOPHiA's platform is sequencer-agnostic, customers are not locked into a single hardware vendor, granting them operational flexibility that proprietary solutions from Illumina cannot match.
The operational moat is fortified by deep switching costs and a powerful network effect the company calls collective intelligence. Once SOPHiA DDM is validated within a laboratory's highly regulated CLIA and CAP workflows and integrated into the hospital's electronic health record system, the friction required to replace it with a competitor's software is immense. This stickiness is reflected in an annualized revenue churn rate of less than 1 percent and a net dollar retention rate of 117 percent in early 2026. Furthermore, as the platform analyzes more data across its global network, its machine learning algorithms become clinically sharper, improving variant calling accuracy. This continuous feedback loop ensures that the 537th hospital joining the network benefits from the genomic insights of the previous 536, creating a data scale advantage that smaller software upstarts cannot easily replicate. This robust market position allows the company to flex significant pricing power, culminating in adjusted gross margins exceeding 75 percent.
Industry Dynamics, Opportunities, and Threats
The secular tailwinds driving the industry are undeniably robust. The proliferation of targeted oncology therapies demands precise companion diagnostics, shifting the standard of care from generalized chemotherapy to genetically guided precision medicine. Additionally, the reimbursement landscape in the United States has materially improved for decentralized testing, reducing denial rates and incentivizing hospitals to bring genomic sequencing in-house. This dynamic provides SOPHiA with a vast opportunity to land new hospital accounts and expand the volume of applications utilized by existing clients.
However, the structural threats facing the company are severe, primarily revolving around its financial profile and capital structure. Despite an asset-light software model and superb gross margins, SOPHiA operates with massive operating expenses tied to enterprise healthcare sales, research and development, and regulatory compliance. The company burned through $19.5 million in cash in the first quarter of 2026 alone. To fund this burn, SOPHiA has relied on a $50 million credit facility from Perceptive Advisors and dilutive at-the-market equity issuance. The debt load introduces rigid covenants, while the continuous need for capital raises the specter of ongoing shareholder dilution. Additionally, the company faces significant foreign exchange exposure. With headquarters in Switzerland, SOPHiA incurs substantial payroll and facility costs in Swiss Francs while generating a large portion of its revenue in U.S. Dollars. A 14 percent appreciation of the Swiss Franc against the dollar over the past year has materially degraded operating margins. Furthermore, intellectual property litigation remains an ever-present industry threat, evidenced by ongoing patent disputes with Guardant Health over liquid biopsy technologies, which continue to drain legal resources and capital.
Growth Drivers and Technological Pipeline
Future revenue growth is heavily contingent on the successful commercialization of high-value, complex diagnostic applications. Liquid biopsy is the company's most potent immediate growth engine. By analyzing circulating tumor DNA from a simple blood draw, liquid biopsies eliminate the need for invasive tissue extraction. SOPHiA's liquid biopsy volumes surged over 100 percent year-over-year in the first quarter of 2026, driven by the rollout of MSK-ACCESS, a decentralized liquid biopsy test co-developed with Memorial Sloan Kettering. The company is currently transitioning this test into a regulated, global companion diagnostic assay, which commands higher average selling prices and drives premium recurring revenue.
Beyond genomics, the company is aggressively expanding into multimodal data analytics through SOPHiA CarePath. This initiative seeks to integrate radiomics, the extraction of deep data from medical imaging like MRI and PET scans, with genomic profiles and digital pathology. By combining these disparate data silos, SOPHiA aims to create a holistic, three-dimensional view of a patient's tumor. Furthermore, the company has partnered with technology behemoths NVIDIA and Microsoft to scale its whole-genome sequencing capabilities, utilizing advanced graphics processing units to reduce processing times tenfold. This technological leap allows SOPHiA to handle the exponentially larger datasets required for whole-genome analysis, opening up new end-markets in rare disease diagnosis and large-scale population health studies.
Disruptive Entrants and Technological Shifts
The bioinformatics layer of clinical genomics is highly susceptible to disruption by artificial intelligence. The most credible threat does not come from small university spin-offs, but from the convergence of big tech and deeply capitalized AI-native health companies. Giants like Microsoft and NVIDIA are building open-source genomic frameworks and foundational AI models for biology. If these base-layer technologies commoditize the secondary analysis of sequence data, SOPHiA will be forced to defend its value entirely at the tertiary interpretation layer. Furthermore, massively funded competitors like Tempus AI are deploying proprietary large language models directly into clinical workflows, combining clinical, genomic, and imaging data at a scale that challenges SOPHiA's decentralized network. If centralized AI platforms can offer drastically superior predictive insights due to absolute data supremacy, hospital administrators may eventually sacrifice the desire for localized testing control in exchange for superior algorithmic performance.
Management Track Record and Execution
Under the leadership of Chief Executive Officer and Co-Founder Jurgi Camblong, management has demonstrated excellent commercial execution but a concerning lack of operating leverage. The company's land-and-expand strategy is working flawlessly at the top line, evidenced by consistent 20 percent-plus revenue growth, record analysis volumes, and world-class net dollar retention. Management has successfully optimized cloud compute architectures to push adjusted gross margins past 75 percent, a commendable feat in a compute-heavy business.
However, the track record regarding profitability is deeply problematic. Since its 2021 initial public offering, the company has consistently pushed back the horizon for breaking even. Operating expenses, particularly sales commissions, bonuses, and administrative overhead, have routinely consumed all the gross profit generated by the platform. Management has recently executed targeted headcount reductions and deployed AI-driven productivity tools to streamline workflows, reaffirming a commitment to approach adjusted EBITDA breakeven by the end of 2026 and cross into positive territory in the second half of 2027. Given the current cash burn trajectory and the debt service obligations, management's ability to execute this precise cost-containment glide path without stalling top-line growth is the singular existential test for the executive team over the next eighteen months.
The Scorecard
SOPHiA GENETICS possesses a highly strategic asset in the SOPHiA DDM platform, functioning as an essential operating system for decentralized precision medicine. The unit economics of the core software are exceptional, characterized by steep switching costs, robust pricing power, and an expanding network effect that locks in hospital customers. Top-line performance continues to compound as the industry transitions toward localized, high-complexity liquid biopsy and multimodal testing, proving that the underlying technology provides tangible clinical value in a massive addressable market.
Conversely, the investment thesis is severely constrained by an operating cost structure that remains disconnected from reality. The company is running a race against its own balance sheet, utilizing expensive debt and dilutive equity to fund a business that structurally burns cash. While the transition from a cash-incinerating growth story to a profitable software enterprise is mathematically possible by late 2027, the margin for error is nonexistent. Any exogenous shocks, whether from strengthening Swiss Francs, adverse patent litigation outcomes, or aggressive pricing actions from capitalized AI competitors, could derail the timeline to self-sustainability and trigger a painful restructuring of the capital base.